SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $118,051.50 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 22,486 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.25, for a total transaction of $118,051.50. Following the completion of the sale, the chairman owned 3,558,807 shares of the company’s stock, valued at $18,683,736.75. This trade represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.28, for a total value of $93,376.80.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total value of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total value of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total value of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.72, for a total value of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,243.00.

SOPHiA GENETICS Trading Up 5.6%

SOPH stock opened at $5.82 on Friday. SOPHiA GENETICS SA has a one year low of $2.92 and a one year high of $6.30. The stock has a market cap of $488.24 million, a price-to-earnings ratio of -11.19 and a beta of 0.96. The company has a fifty day moving average price of $5.16 and a two-hundred day moving average price of $4.98. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently modified their holdings of SOPH. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS in the 1st quarter worth about $50,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS in the 3rd quarter valued at about $49,000. Perkins Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS during the 4th quarter worth approximately $49,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the fourth quarter worth approximately $54,000. Finally, XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS during the fourth quarter worth approximately $55,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. BTIG Research restated a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.